Characterization and formulation into solid dosage forms of a novel bacteriophage lytic against Klebsiella oxytoca.

This study reports a novel bacteriophage specific for Klebsiella oxytoca which can be formulated into solid dosage forms appropriate for potential delivery in testing as a therapy to modulate gut microbiome during antibiotic therapies.